Enanta Pharmaceuticals, Inc.

ENTA · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders4.7%

Institutions94.3%

Public / Other

Income Statement

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Total money the company brought in from its core business during the period, before any costs are subtracted.	$65.32M	$67.64M	$79.20M	$86.16M	$97.07M	$122.47M	$205.20M	$206.63M	$102.81M	$88.27M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$85.35M	-$121.69M	-$137.21M	-$123.84M	-$109.57M	-$41.64M	$36.74M	$88.33M	$24.61M	$30.84M
Operating income as a percentage of revenue.	-130.7%	-179.9%	-173.2%	-143.7%	-112.9%	-34.0%	17.9%	42.7%	23.9%	34.9%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$81.89M	-$116.05M	-$133.82M	-$121.75M	-$79.00M	-$36.17M	$46.38M	$71.96M	$17.71M	$21.67M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.00	$-5.00	$-6.00	$-5.00	$-3.92	$-1.81	$2.37	$3.00	$0.00	$1.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.00	$-5.00	$-6.00	$-5.00	$-3.92	$-1.81	$2.21	$3.00	$0.00	$1.00

Balance Sheet

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Cash and highly liquid short-term investments the company can access almost immediately.	$32.30M	$37.23M	$85.39M	$43.99M	$57.21M	$87.13M	$51.23M	$63.90M	$65.67M	$16.58M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$280.73M	$376.65M	$462.27M	$375.41M	$438.79M	$486.13M	$489.83M	$414.23M	$326.64M	$281.28M
Everything the company owes — debt, unpaid bills, and other obligations.	$216.01M	$247.84M	$245.54M	$54.08M	$39.36M	$30.55M	$27.34M	$20.55M	$24.96M	$11.34M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$64.72M	$128.81M	$216.74M	$321.33M	$399.43M	$455.58M	$462.49M	$393.68M	$301.68M	$269.94M

Cash Flow Statement

	2025-09-30	2024-09-30	2023-09-30	2022-09-30	2021-09-30	2020-09-30	2019-09-30	2018-09-30	2017-09-30	2016-09-30
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$19.27M	-$78.76M	-$103.15M	-$84.78M	-$70.00M	$7.09M	$71.42M	$29.22M	$52.65M	$35.81M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$12.90M	$17.95M	$9.06M	$2.13M	$750000	$1.45M	$5.42M	$2.98M	$2.51M	$4.74M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$32.17M	-$96.71M	-$112.21M	-$86.91M	-$70.75M	$5.64M	$66.00M	$26.24M	$50.15M	$31.07M

	You	Peer avg
Revenue Growth	-21.6%	+62.4%
ROE	-70.1%	-34.9%

Enanta Pharmaceuticals, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison